A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
Public ClinicalTrials.gov record NCT05831189. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial will be initiated to explore whether RBX2660 (REBYOTA®) could be suitable for administration by the practice of colonoscopy. More specifically, the purpose of this trial is to explore the safety and clinical effectiveness of RBX2660 when delivered by colonoscopy to adults with rCDI. The experience of physicians will be documented through a physician-experience questionnaire to explore the usability of RBX2660 in clinical practice for colonoscopic administration. Furthermore, to explore the patient-experience of RBX2660 treatment, each trial participant will be offered to undergo a structured interview.
Study identification
- NCT ID
- NCT05831189
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 41 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 20, 2023
- Primary completion
- Jan 16, 2025
- Completion
- Jan 16, 2025
- Last update posted
- Apr 23, 2026
2023 – 2025
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ferring Investigational Site | North Little Rock | Arkansas | 72117 | — |
| Ferring Investigational Site | Camarillo | California | 93012 | — |
| Ferring Investigational Site | Hamden | Connecticut | 06518 | — |
| Ferring Investigational Site | Idaho Falls | Idaho | 83404 | — |
| Ferring Investigational Site | Gurnee | Illinois | 60031 | — |
| Ferring Investigational Site | Shreveport | Louisiana | 71105 | — |
| Ferring Investigational Site | Plymouth | Minnesota | 55446 | — |
| Ferring Investigational Site | Rochester | Minnesota | 55905 | — |
| Ferring Investigational Site | Cleveland | Ohio | 44195 | — |
| Ferring Investigational Site | Oklahoma City | Oklahoma | 73102 | — |
| Ferring Investigational Site | Burke | Virginia | 22015 | — |
| Ferring Investigational Site | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05831189, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05831189 live on ClinicalTrials.gov.